Citi raised the firm’s price target on Travere Therapeutics (TVTX) to $35 from $31 and keeps a Buy rating on the shares. The firm anticipates continued growth for Filspari in 2025. The high overlap of target nephrologists treating both IgA nephropathy and focal segmental glomerulosclerosis should support a strong uptake in the latter, the analyst tells investors in a research note. Citi sees further upside in Travere, saying the shares are not sufficiently reflecting FSGS.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics: Strong Growth Potential and Strategic Advancements Justify Buy Rating
- Travere Therapeutics’ Earnings Call Reveals Growth and Challenges
- Travere Therapeutics price target raised to $30 from $24 at TD Cowen
- Travere Therapeutics Posts Strong 2024 Financial Results
- Strong Growth Potential and Strategic Advancements Drive Buy Rating for Travere Therapeutics